Merck KGaA Plays Key Supporting Role For Coronavirus Vaccines
Posts Strong Q3 Sales Growth
The German drugmaker is seeing growing demand for its services from peers in the pharma world that are looking to develop vaccines to tackle the COVID-19 pandemic.
You may also be interested in...
Pfizer-partnered Bavencio has struggled to compete with other checkpoint inhibitors like Keytruda, Opdivo, Imfinzi and Tecentriq, but could carve out a lucrative niche in first-line urothelial carcinoma.
Key cancer asset is still looking for a Phase III validation after failing to outperform Keytruda in challenging frontline NSCLC setting.
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Business development is key topic for Amgen and Vertex; BioNTech talks COVID-19 vaccine supply while Merck KGAA's new CEO pledges to rise to meet the challenges posed by COVID-19.